Organovo Holdings, Inc. (ONVO)

1.0000 +0.0119 (+1.20%) At close: 04:00PM EDT

Organovo Holdings, Inc.

11555 Sorrento Valley Road
Suite 100
San Diego, CA 92121
United States
(858) 224-1000
https://www.organovo.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 18

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Keith E. Murphy	Executive Chairman	762.74k	N/A	1972
Mr. Thomas P. Hess CPA, MBA	President & CFO	199.32k	N/A	1964
Ms. Vaidehi Joshi	Director of Discovery Biology & Director	91.8k	N/A	1987
Dr. Curtis M. Tyree Ph.D.	Senior Vice President of Strategy & Business Development	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Corporate governance

Organovo Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.